Results 81 to 90 of about 56,599 (248)
Effect of etanercept on cardiac function.
, 2014 (A) The effect of etanercept on LVEF. (B) The effect of etanercept on LVEDP. (C) The effect of etanercept on –dp/dx max. (D) The effect of etanercept on +dp/dx max.
Mei Yang (51996) +3 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu +4 more
wiley +1 more source
Etanercept in the treatment of plaque psoriasis
, 2009 Thao U Nguyen, John KooDepartment of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, San Francisco, California, USAAbstract: Etanercept is approved for the treatment of moderate to severe plaque psoriasis at a ...
Thao U Nguyen, John Koo
core
Etanercept for the treatment of rheumatoid arthritis.
, 2003 BACKGROUND: Etanercept is a soluble tumour necrosis factor alpha-receptor DMARD for the treatment of rheumatoid arthritis (RA). OBJECTIVES: To assess the efficacy and safety of etanercept for the treatment of RA.
Barbara BTB Blumenauer +15 more
core +1 more source
Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans
Clinical Pharmacology &Therapeutics, EarlyView.Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley +1 more source
, 2013 Technology: Infliximab and comparator biological such as adalimumab, etanercept, golimumab. Conditions: Ankylosing spondylitis (AS) Issue: Infliximab is registered to be used in patients with AS.
Péntek, Márta
core
Adjunctive etanercept reduces TB-associated pathology.
, 2013 Hematoxylin and eosin staining (20x and 200x – inset) was performed on lung tissues. Images shown are representative of sections obtained from 4 animals per group. Each time-point is shown in weeks on the individual images.
Ciaran Skerry (317997) +4 more
core +1 more source
Etanercept In the treatment of AA-amyloidosis in juvenile rheumatoid arthritis
Научно-практическая ревматология, 2004 Objective. To study effect of etanercept, an antagonist of serum A amyloid production in the AA amyloidosis treatment in juvenile idiopathic arthritis (JIA). Material and methods.
H Mihels
doaj +1 more source
Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications
Barrier Immunity, EarlyView.A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu +9 more
wiley +1 more source
Pediatric Rheumatology Online JournalBackground Etanercept has been studied in doses up to 0.8 mg/kg/week (max 50 mg/week) in juvenile idiopathic arthritis (JIA) patients. In clinical practice higher doses are used off-label, but evidence regarding the relation with outcomes is lacking.
Bastiaan T. van Dijk +10 more
doaj +1 more source